2024-512642-42-00RecruitingPhase 3
Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any stage, any biological risk) and pediatric patients with Hodgkin lymphoma and non-Hodgkin lymphoma needing radiation therapy on thyroid site - WINHYPO 2021
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Sept 2026
Brief summary (registry, in English)
To evaluate if the incidence of hypothyroidism after radiation therapy in medulloblastoma, Hodgkin and non-Hodgkin lymphomas can be reduced by TSH suppression during irradiation.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- First submitted
- 18 Mar 2024
- Start date
- 13 Dec 2021
- Lead sponsor
- Fondazione IRCCS Istituto Nazionale Dei Tumori
- Diseases
- Childhood cancers, Hodgkin lymphoma
- EU CT number
- 2024-512642-42-00
- EudraCT number
- 2021-001385-38
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 65
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with medulloblastoma, Hodgkin lymphoma or non-Hodgkin lymphoma who are about to have radiotherapy that includes the thyroid gland, and who have no earlier thyroid underactivity.
- Sex
- All sexes can join.
- Disease stage
- Medulloblastoma (any stage, any biological risk), Hodgkin lymphoma or non-Hodgkin lymphoma. Radiotherapy planned to include the thyroid gland tissue.
- Earlier treatment
- Must not yet have had radiotherapy that included the thyroid gland. Must not have had thyroid underactivity (primary or secondary hypothyroidism) before.
Main reasons for not taking part
- Radiotherapy including the thyroid gland already given
- Previous primary or secondary hypothyroidism
- No signed consent
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any patient with medulloblastoma, Hodgkin/non-Hodgkin Lymphoma after radiotherapy including thyroid parenchyma;
Other
- Not signed consent.
Who the study is looking for
- Any patient with medulloblastoma, Hodgkin/non-Hodgkin Lymphoma BEFORE RADIOTHERAPY (RT) PLANNING INCLUDING THYROID PARENCHYMA without previous primary or secondary hypothyroidism;
- Written informed consent prior to any study-specific analysis and/or data collection.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.